J M S Bartlett
Overview
Explore the profile of J M S Bartlett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Earl H, Hiller L, Dunn J, Vallier A, Bowden S, Jordan S, et al.
Br J Cancer
. 2012 Oct;
107(8):1257-67.
PMID: 23047592
Background: The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy...
22.
Fontein D, Houtsma D, Hille E, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, et al.
Ann Oncol
. 2012 Aug;
23(12):3091-3097.
PMID: 22865782
Background: Many adverse events (AEs) associated with aromatase inhibitors (AIs) involve symptoms related to the depletion of circulating estrogens, and may be related to efficacy. We assessed the relationship between...
23.
Munro A, Twelves C, Thomas J, Cameron D, Bartlett J
Br J Cancer
. 2012 May;
107(1):71-4.
PMID: 22644297
Background: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An explanation may be chromosome instability (CIN); a frequent event in solid tumours associated...
24.
Starczynski J, Atkey N, Connelly Y, OGrady T, Campbell F, Di Palma S, et al.
Am J Clin Pathol
. 2012 Mar;
137(4):595-605.
PMID: 22431536
International and national guidelines highlight the importance of accuracy, reproducibility, and quality control of in situ hybridization (ISH) methods for testing breast carcinomas. However, few guidelines cover the reporting of...
25.
Bartlett J, Starczynski J, Atkey N, Kay E, OGrady A, Gandy M, et al.
J Clin Pathol
. 2011 Jun;
64(8):649-53.
PMID: 21690244
These guidelines supplement existing guidelines on HER2 testing by immunohistochemistry and in-situ hybridisation(ISH) methods in the UK. They provide a specific focus on aspects of guidance relevant to HER2 ISH...
26.
Bartlett J, Campbell F, Ibrahim M, OGrady A, Kay E, Faulkes C, et al.
Am J Clin Pathol
. 2010 Dec;
135(1):157-62.
PMID: 21173138
We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH)...
27.
Macaskill E, Bartlett J, Sabine V, Faratian D, Renshaw L, White S, et al.
Breast Cancer Res Treat
. 2010 Oct;
128(3):725-34.
PMID: 20941539
mTOR plays a key role in tumor cell cycle control, proliferation, and survival. RAD001 (everolimus) is a novel macrolide that inhibits mTOR and thus downstream signaling pathways. 31 post-menopausal women...
28.
Aubele M, Spears M, Ludyga N, Braselmann H, Feuchtinger A, Taylor K, et al.
Br J Cancer
. 2010 Aug;
103(5):663-7.
PMID: 20700126
Background: Protein tyrosine kinase 6 (PTK6; breast tumour kinase) is overexpressed in up to 86% of the invasive breast cancers, and its association with the oncoprotein human epidermal growth factor...
29.
Munro A, Cameron D, Bartlett J
Oncogene
. 2010 Aug;
29(38):5231-40.
PMID: 20676126
The search for a predictive marker of sensitivity to anthracycline-based chemotherapy has proven challenging. Despite human epidermal growth factor receptor 2 (HER2) being a strong prognostic marker in breast cancer,...
30.
Spears M, Kenicer J, Munro A, Bartlett J
Biomark Med
. 2010 May;
2(4):397-407.
PMID: 20477393
The type I receptor tyrosine kinase (RTK) family of proteins play an essential role in the progression of early breast cancer. Our understanding of the role of these proteins has...